Further therapeutic options are urgently required for patients with biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung and bladder cancer, especially following failure of standard treatment. Mouse double minute 2 (MDM2) is amplified in ∼5–6% cases BTC, ∼1% PDAC, ∼4% adenocarcinomas ∼7% cancers. MDM2, an E3 ubiquitin ligase, endogenous negative regulator p53. Preclinical e...